Imlygic Market Report 2026

Imlygic Market Overview

• The Imlygic market growth in the historic period has been driven by limited options for unresectable melanoma, early immunotherapy breakthroughs • Market expansion is supported by expansion of cancer immunotherapy pipelines, increased combination oncology trials • Growth Driver: The Impact Of Rising Melanoma Cases On The Growth Of The Market • North America was the largest region in 2025.

What Is Covered Under Imlygic Market?

Imlygic is a prescription medication used to treat certain types of cancer. It is an oncolytic viral therapy that uses a genetically modified virus to target and destroy cancer cells. Imlygic is derived from the herpes simplex type 1 (HSV-1) and is approved for treating melanoma lesions that cannot be surgically removed. The main patient demographics of imlygic are pediatric patients and adult patients. Pediatric patients refer to individuals from birth to 18 years old who are under medical care. Imlygic (talimogene laherparepvec) may be investigated in clinical trials for specific cancers like melanoma. It is distributed through various channels such as hospitals, specialty clinics, online pharmacies, and retail pharmacies for applications such as melanoma treatment, combination therapy, and other cancer types.

What Is The Imlygic Market Growth Forecast?

The growth in the forecast period can be attributed to expansion of cancer immunotherapy pipelines, increased combination oncology trials, growing investment in viral therapeutics, rising melanoma diagnosis rates, advancements in genetic modification technologies. Major trends in the forecast period include growth of oncolytic viral therapies, rising interest in immuno oncology, expansion of injectable cancer therapies, focus on localized tumor treatment, increasing combination therapy approaches.

Global Imlygic Market Segmentation

1) By Patient Demographics: Pediatric Patients, Adult Patients 2) By Distribution Channel: Hospitals, Specialty Clinics, Online Pharmacies, Retail Pharmacies 3) By Application: Melanoma Treatment, Combination Therapy, Other Cancer Types

What Are The Drivers Of The Imlygic Market?

The rising incidence of melanoma is expected to propel the growth of the imlygic market going forward. Melanoma is a type of skin cancer that develops in the melanocytes, the cells responsible for producing pigment in the skin. The incidence of melanoma is increasing due to factors such as prolonged sun exposure, tanning bed use, and genetic predisposition. Imlygic (talimogene laherparepvec) is an oncolytic viral therapy injected directly into melanoma tumors to promote local tumor destruction and systemic anti-tumor immune response. For instance, in December 2023, according to the National Library of Medicine, a US-based biomedical library, the number of melanoma cases in the EU-27 (27 member countries of the European Union (EU) ) was 101,510 in 2022, and it is expected to increase to 115,540 by 2040. Therefore, the rising incidence of melanoma is driving the growth of the imlygic industry. The global expansion of healthcare infrastructure is expected to propel the growth of the imlygic going forward. Healthcare infrastructure refers to the physical and organizational structures, facilities, resources, and systems necessary for delivering healthcare services to a population. The aging global population, the increase in chronic diseases, and technological advancements drive the global expansion of healthcare infrastructure. The progress of imlygic relies on robust healthcare infrastructure to support its specialized storage, administration, and coordinated delivery as an oncolytic therapy. For instance, in September 2024, according to the statistics published by Cross River Therapy, a US-based provider of ABA therapy services, the U.S. pharmaceutical industry generated $550 billion in revenue, with Americans spending $576.9 billion on medicine in 2021 and projected spending is expected to increase to $605-$635 billion by 2025. Therefore, the global expansion of healthcare infrastructure is driving the growth of the imlygic industry. The rise in research and development funding for cancer is expected to drive the growth of the imlygic market going forward. Cancer research and development funding is the financial support for advancing cancer treatment, prevention, and research initiatives. The rising global cancer burden, the demand for innovative therapies, and advancements in precision medicine drive the increase in cancer research and development funding. Increasing cancer research and development funding accelerates innovation, clinical trials, and awareness, fostering advancements and broader adoption of therapies such as imlygic. For instance, in July 2025, according to the National Cancer Institute US-based government agency reported that in fiscal year 2023, the NCI had $7.2 billion in available funding (including $216 million from the Cures Act), marking a 5.7% increase, or $387.5 million more than the prior year. Therefore, the increasing research and development funding for cancer is driving the growth of the imlygic industry.

Key Players In The Global Imlygic Market

Major companies operating in the imlygic market are Amgen Inc.

Regional Insights

North America was the largest region in the imlygic market in 2025. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

What Defines the Imlygic Market?

The imlygic market consists of sales of imlygic intralesional injections. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Imlygic Market Report 2026?

The imlygic market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the imlygic industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.